UNSPSC 51295107: Dazadrol maleate

This classification denotes an antidepressant agent with the molecular formula C15H14ClN3O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T87PS4H85N, chemically known as 2-pyridinemethanol, alpha-(p-chlorophenyl)-alpha-2-imidazolin-2-yl-, maleate but more generally known as dazadrol maleate, which bears US NIH Compound Identifier 6433894. Most nations, for tariff and trade purposes, schedule dazadrol maleate under HS 29333999 and SITC 51574. As of Q4 2014, DAZADROL MALEATE remains US FDA's Preferred Term for this commodity.

Dazadrol maleate bears US NLM identifiers UMLS ID C2827130 and NCI Concept Code C83655. SMILES: C1CCNC(C1)C(C2CCC(CC2)CL)(C3=NCCN3)O.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51295107 Dazadrol maleate is a Commodity code that nominally names a specific pharmaceutical active ingredient, but recent state and local solicitations tagged under this code show minimal direct relevance to dazadrol itself. Instead, the code appears in procurement activity focused on naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and pharmacy benefit program infrastructure. State and local governments are using this code—or misusing it—to buy naloxone products for community health and opioid response, generic OTC and prescription pharmaceuticals through cooperative purchasing vehicles, and to solicit vendor capabilities for direct-to-manufacturer pharmacy programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration). The activity is driven by public health demand for opioid-response products and cost management in government pharmacy benefit programs rather than by procurement of dazadrol specifically.

Recent opportunities span Florida, Texas, and Minnesota through mid-2026. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: this appears to be a historical posting with a past-date response window). Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, requesting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to explore direct contracting models between state agencies and pharmaceutical manufacturers outside traditional PBM and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline, establishing multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) across Minnesota, Oregon, and other participating jurisdictions, with awards effective July 1, 2026. The code shows activity across health agencies and cooperative purchasing bodies but little direct procurement of dazadrol maleate as a named product.